Theralink Technologies Company Description
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States.
The company offers patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development.
It also provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments.
In addition, the company’s data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology.
The company was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020.
Theralink Technologies, Inc.is headquartered in Golden, Colorado. Theralink Technologies, Inc. is a subsidiary of Theralink Technologies, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
Contact Details
Address: 15000 West 6th Avenue Golden, Nevada 80401 United States | |
| Phone | 888 585 4923 |
| Website | theralink.com |
Stock Details
| Ticker Symbol | THER |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| ISIN Number | US88339Q1094 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael I. Ruxin M.D. | Chief Medical Officer and Director |
| Trevor McCartney | Vice President of Sales Operations and Strategic Partnerships |